Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

Recent preclinical studies revealed the efficacy of combined use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib in breast and prostate cancers. The current study investigated the effect of such drug combination on ovarian cancer. Here we showed that combined inhibition of PI3K and PARP effecti...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Wang, Dong, Wang, Min, Jiang, Nan, Zhang, Yuan, Bian, Xing, Wang, Xiaoqing, Roberts, Thomas M., Zhao, Jean J., Liu, Pixu, Cheng, Hailing
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4914348/
https://ncbi.nlm.nih.gov/pubmed/26909613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7549
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы